Pediatric antiphospholipid syndrome.

摘要: APS is rare in the pediatric age, but it represents an interesting phenomenon because most of known "second hit" risk factors such as atherosclerosis, smoking, hypertension, contraceptive hormonal treatment, and pregnancy are not present childhood. This could also be reason for prevalence some clinical manifestations rather than others PAPS. On other hand, increased frequency infectious processes childhood age likely responsible relatively high non-pathogenic transient aPL. Such points raise problem a different diagnosis or monitoring approach APS. Of particular interest special entity neonatal APS, which vivo model acquired autoimmune disease, transplacentally aPL cause thrombosis newborn. International registries currently place; epidemiologic, clinical, laboratory re-search will help to shed light on all still obscure aspects this fascinating disorder very young. Finally, treatment less aggressive overall given reluctance anticoagulate children over long term. Studies outcome relative risks prolonged anticoagulation necessary determine type duration therapy.